Business Context and Reporting Period
CalciMedica, Inc. (Nasdaq: CALC) filed a Form 8-K on June 27, 2024, to disclose Regulation FD information regarding topline data from the Phase 2b CARPO clinical trial. The trial evaluated the company's lead candidate, Auxora, for the treatment of acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).
Key Financial Metrics
This filing is a current report focused on clinical trial results and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Results
The filing details positive topline results from the CARPO trial, which enrolled 216 patients randomized into four groups (high, medium, low dose, and placebo). Key efficacy findings include:
- Primary Endpoint: In the pre-specified hyper-inflammatory subgroup, Auxora demonstrated a statistically significant dose response for time to solid food tolerance. The high dose group showed a 1.9-day improvement (41.0% relative risk reduction) compared to placebo (4.7 days).
- Severe Organ Failure: A statistically significant dose response was observed. Severe organ failure occurred in 3.8% of high-dose patients and 3.6% of medium-dose patients, compared to 9.4% in the placebo group, representing a 59.6% to 61.7% relative risk reduction.
- Hospital Stay: The median length of stay was 5.0 days for placebo. The high-dose group showed a 1.0-day reduction in median stay. In the hyper-inflammatory subgroup, the high and medium dose groups showed reductions of 1.5 and 1.9 days, respectively.
- Prolonged Stay: No patients in the high-dose group remained in the hospital longer than 21 days, compared to 5.7% in the placebo group.
Guidance, Outlook, and Risks
Outlook and Next Steps:
- The Company intends to present additional data, including CT scan analyses, at a medical meeting later in 2024.
- Management plans to move forward rapidly with a pivotal trial of Auxora for AP.
- Ongoing trials include the Phase 1/2 CRSPA trial for pediatric asparaginase-induced pancreatic toxicity and the planned Phase 2 KOURAGE trial for acute kidney injury.
- Auxora was well-tolerated. Treatment-emergent serious adverse events (TESAEs) were reported in 14 (high dose), 21 (medium dose), and 23 (low dose) patients versus 20 in the placebo group.
- None of the TESAEs in the high and medium dose groups were deemed drug-related.
- Deaths occurred in 1 placebo patient and 1 medium-dose patient; there were no deaths in the high or low-dose groups.
- Forward-looking statements are subject to risks including regulatory approval uncertainties, clinical trial outcomes, and the need for additional capital.
- The filing explicitly states that preliminary results may not be indicative of future results.
Investor Verification Checklist
- Verify the specific statistical significance values (p-values) for the primary and secondary endpoints in the full clinical study report or subsequent presentations.
- Confirm the timeline and design details for the planned pivotal Phase 3 trial.
- Review the company's most recent Form 10-Q or 10-K for current cash runway and capital requirements to fund the pivotal trial.
- Monitor upcoming medical conference presentations for the detailed CT scan analysis data.